Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Receivables: 2023-2024

Historic Receivables for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $4.0 million.

  • BioLineRx's Receivables fell 92.67% to $281,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $10.1 million, marking a year-over-year change of. This contributed to the annual value of $4.0 million for FY2024, which is 232.83% up from last year.
  • Per BioLineRx's latest filing, its Receivables stood at $4.0 million for FY2024, which was up 232.83% from $1.2 million recorded in FY2023.
  • In the past 5 years, BioLineRx's Receivables registered a high of $4.0 million during FY2024, and its lowest value of $1.2 million during FY2023.
  • Over the past 2 years, BioLineRx's median Receivables value was $2.6 million (recorded in 2023), while the average stood at $2.6 million.
  • Data for BioLineRx's Receivables shows a peak YoY spiked of 232.83% (in 2024) over the last 5 years.
  • Over the past 2 years, BioLineRx's Receivables (Yearly) stood at $1.2 million in 2023, then soared by 232.83% to $4.0 million in 2024.